Sylvan C. Baca

11.1k total citations
25 papers, 784 citations indexed

About

Sylvan C. Baca is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Sylvan C. Baca has authored 25 papers receiving a total of 784 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 9 papers in Molecular Biology and 8 papers in Oncology. Recurrent topics in Sylvan C. Baca's work include Prostate Cancer Treatment and Research (11 papers), Cancer Genomics and Diagnostics (5 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Sylvan C. Baca is often cited by papers focused on Prostate Cancer Treatment and Research (11 papers), Cancer Genomics and Diagnostics (5 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Sylvan C. Baca collaborates with scholars based in United States, Italy and Canada. Sylvan C. Baca's co-authors include Levi A. Garraway, Andrew J. Heron, Mark I. Wallace, Mark A. Rubin, Matthew L. Freedman, Namrata D. Udeshi, Jean‐Philippe Theurillat, Steven A. Carr, Holger Moch and Mirjam Blattner and has published in prestigious journals such as Science, Nucleic Acids Research and Nature Medicine.

In The Last Decade

Sylvan C. Baca

21 papers receiving 775 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sylvan C. Baca United States 12 458 280 195 156 75 25 784
Letícia Ferro Leal Brazil 17 399 0.9× 198 0.7× 296 1.5× 212 1.4× 105 1.4× 61 882
Eva Colás Spain 21 624 1.4× 185 0.7× 408 2.1× 231 1.5× 28 0.4× 42 1.2k
Lindsay Kilburn United States 17 462 1.0× 178 0.6× 177 0.9× 189 1.2× 23 0.3× 68 1.1k
Robert W. Hsieh United States 8 625 1.4× 241 0.9× 223 1.1× 656 4.2× 16 0.2× 8 1.4k
Ulrich Hermanto United States 7 315 0.7× 154 0.6× 69 0.4× 113 0.7× 62 0.8× 7 584
Jenny Bazov Canada 7 358 0.8× 438 1.6× 363 1.9× 318 2.0× 71 0.9× 7 986
Mario Caccese Italy 17 253 0.6× 224 0.8× 211 1.1× 242 1.6× 60 0.8× 70 883
Yunfeng Yuan China 15 418 0.9× 140 0.5× 229 1.2× 112 0.7× 19 0.3× 32 769
Marina Chekmareva United States 16 553 1.2× 150 0.5× 188 1.0× 307 2.0× 15 0.2× 35 957
J. Yamashita Japan 12 335 0.7× 106 0.4× 158 0.8× 198 1.3× 34 0.5× 33 742

Countries citing papers authored by Sylvan C. Baca

Since Specialization
Citations

This map shows the geographic impact of Sylvan C. Baca's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sylvan C. Baca with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sylvan C. Baca more than expected).

Fields of papers citing papers by Sylvan C. Baca

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sylvan C. Baca. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sylvan C. Baca. The network helps show where Sylvan C. Baca may publish in the future.

Co-authorship network of co-authors of Sylvan C. Baca

This figure shows the co-authorship network connecting the top 25 collaborators of Sylvan C. Baca. A scholar is included among the top collaborators of Sylvan C. Baca based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sylvan C. Baca. Sylvan C. Baca is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gulati, Gunsagar S., et al.. (2026). Precision Oncology 2.0: Guiding Magic Bullets With Expression-Based Liquid Biopsy. Journal of Clinical Oncology. JCO2501983–JCO2501983.
2.
Clark, Travis, John Canniff, Renée Maria Saliby, et al.. (2025). Epigenomic profiling of circulating chromatin for early detection and monitoring of neuroendocrine prostate cancer.. Journal of Clinical Oncology. 43(5_suppl). 253–253.
3.
Zhang, Qianxia, et al.. (2024). Mechanism for controlled assembly of transcriptional condensates by Aire. Nature Immunology. 25(9). 1580–1592. 4 indexed citations
4.
Davis, James, Lingkun Gu, Sylvan C. Baca, et al.. (2024). Disruption of the OsWRKY71 transcription factor gene results in early rice seed germination under normal and cold stress conditions. BMC Plant Biology. 24(1). 1090–1090. 4 indexed citations
5.
Zarif, Talal El, Paul Stockhammer, Emre Yekedüz, et al.. (2024). ERBB2 mutations and association with molecular phenotype in urothelial carcinoma.. Journal of Clinical Oncology. 42(16_suppl). 4590–4590.
6.
7.
Hwang, Justin H., Sachin Kumar Deshmukh, Sharon Wu, et al.. (2024). The opposing effects of Class 1B and Class 2 FOXA1 mutations in prostate cancer.. Journal of Clinical Oncology. 42(4_suppl). 216–216. 1 indexed citations
8.
Moon, Intae, Jaclyn LoPiccolo, Sylvan C. Baca, et al.. (2023). Machine learning for genetics-based classification and treatment response prediction in cancer of unknown primary. Nature Medicine. 29(8). 2057–2067. 51 indexed citations
9.
Morova, Tunç, Yi Ding, Chia-Chi Flora Huang, et al.. (2022). Optimized high-throughput screening of non-coding variants identified from genome-wide association studies. Nucleic Acids Research. 51(3). e18–e18. 8 indexed citations
10.
Shi, Xiaolei, Sylvan C. Baca, Justin M. Drake, et al.. (2022). Integrative molecular analyses define correlates of high B7-H3 expression in metastatic castrate-resistant prostate cancer. npj Precision Oncology. 6(1). 80–80. 18 indexed citations
11.
Lü, Xiaodong, Ka-wing Fong, Galina Gritsina, et al.. (2022). HOXB13 suppresses de novo lipogenesis through HDAC3-mediated epigenetic reprogramming in prostate cancer. Nature Genetics. 54(5). 670–683. 58 indexed citations
12.
McGregor, Bradley A., Wanling Xie, Mehmet Asım Bilen, et al.. (2022). Initial results of a phase II study of nivolumab(N) and ipilimumab(I) in genitourinary malignancies with neuroendocrine differentiation.. Journal of Clinical Oncology. 40(6_suppl). 569–569. 1 indexed citations
13.
Ganguli, Dwaipayan, Maxim Kobelev, Olena Sivak, et al.. (2022). ASCL1 activates neuronal stem cell-like lineage programming through remodeling of the chromatin landscape in prostate cancer. Nature Communications. 13(1). 2282–2282. 68 indexed citations
14.
Giambartolomei, Claudia, Ji-Heui Seo, Malika Freund, et al.. (2021). H3K27ac HiChIP in prostate cell lines identifies risk genes for prostate cancer susceptibility. The American Journal of Human Genetics. 108(12). 2284–2300. 25 indexed citations
15.
Nuzzo, Pier Vitale, Jacob E. Berchuck, Sándor Spisák, et al.. (2020). Sensitive detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes.. Journal of Clinical Oncology. 38(6_suppl). 728–728. 3 indexed citations
16.
Rasool, Reyaz ur, Ramakrishnan Natesan, Qu Deng, et al.. (2019). CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer through MED1 Inactivation. Cancer Discovery. 9(11). 1538–1555. 86 indexed citations
17.
Theurillat, Jean‐Philippe, Namrata D. Udeshi, Wesley J. Errington, et al.. (2014). Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. Science. 346(6205). 85–89. 168 indexed citations
18.
Prandi, Davide, Sylvan C. Baca, Alessandro Romanel, et al.. (2014). Unraveling the clonal hierarchy of somatic genomic aberrations. Genome biology. 15(8). 439–439. 59 indexed citations
19.
Baca, Sylvan C. & Levi A. Garraway. (2012). The genomic landscape of prostate cancer. Frontiers in Endocrinology. 3. 69–69. 37 indexed citations
20.
Baca, Sylvan C., et al.. (1994). Acute myositis and dermatitis as the initial presentation of sarcoidosis.. PubMed. 11(5). 553–6. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Letícia Ferro Leal Breakdown of academic impact, for papers by Eva Colás Breakdown of academic impact, for papers by Lindsay Kilburn Breakdown of academic impact, for papers by Robert W. Hsieh Breakdown of academic impact, for papers by Ulrich Hermanto Breakdown of academic impact, for papers by Jenny Bazov Breakdown of academic impact, for papers by Mario Caccese Breakdown of academic impact, for papers by Yunfeng Yuan Breakdown of academic impact, for papers by Marina Chekmareva Breakdown of academic impact, for papers by J. Yamashita
Rankless by CCL
2026